SF
CRDL

Summit Financial’s Cardiol Therapeutics CRDL Stock Holding History

Summit Financial’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$140K Hold
104,059
– – ﹤0.01% 1367
2025
Q4 		$99.3K Sell
104,059
-24,950
-19% -$26.1K ﹤0.01% 1272
2025
Q3 		$138K Buy
+129,009
New +$157K ﹤0.01% 1215

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Summit Financial's CRDL Position: Q1 2026 in Review

Summit Financial held its Cardiol Therapeutics (CRDL) position steady in Q1 2026 at 104,059 shares worth $140K. The position accounts for ﹤0.01% of the portfolio, ranked #1367.

Summit Financial first reported a position in CRDL in Q3 2025 and has held it in 3 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Summit Financial held 104,059 shares of Cardiol Therapeutics worth $140K as of Q1 2026.
  • Summit Financial left its Cardiol Therapeutics share count unchanged in Q1 2026.
  • Cardiol Therapeutics made up ﹤0.01% of Summit Financial's portfolio in Q1 2026, its #1367 holding.
  • Summit Financial first reported a position in Cardiol Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Summit Financial's 13F filing for Q1 2026, filed 15 May 2026.